What the Breakthrough T1D grant means for MannKind

The new Breakthrough T1D grant for MannKind (MNKD) and its INHALE-1 study puts Afrezza’s pediatric program in focus, coming shortly after FDA approval for children aged 6 and older.

For you as an investor, the grant does two things at once. It validates Afrezza as a research priority within the type 1 diabetes community, and it helps support clinical work that MannKind would otherwise need to fund on its own.

The INHALE-1 trial is centered on newly diagnosed youth aged 10 to under 18, using Afrezza at mealtimes alongside once daily basal insulin. The study follows participants through a 13 week main phase, with an optional 26 week extension for those who continue Afrezza.

While this is a single arm trial rather than a head to head comparison, it is set up to capture a mix of hard outcomes and real world experience, including caregiver and participant satisfaction with inhaled insulin early in the treatment journey.

Against this backdrop, MannKind’s recent 80.8% 90 day share price return and 34.52% 30 day share price return point to strengthening momentum, even though the year to date share price return is down 19.29% and the 1 year total shareholder return is 25.56%.

If Afrezza’s pediatric progress has you thinking more broadly about healthcare opportunities, this could be a good moment to scan other specialised drug and device companies through a dedicated screener such as 20 top founder-led companies

With MannKind shares up 34.52% over 30 days and 80.8% over 90 days, yet still showing an intrinsic discount of 11.7% and trading 68% below analyst targets, is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 40.5% Undervalued

The most followed narrative on MannKind currently points to a fair value of $7.59 per share versus a last close of $4.52. This frames the recent share price strength against a still sizeable implied upside.

Multiple late-stage pipeline programs (inhaled clofazimine for NTM and nintedanib DPI for IPF) are progressing toward key regulatory and clinical milestones, benefiting from expedited pathways and growing unmet need in chronic respiratory diseases, with the potential to significantly diversify and expand future revenues.

Curious what is driving that fair value gap for MannKind? The narrative focuses on changing profit margins, faster earnings growth and a richer future earnings multiple. The exact mix of those assumptions is where the story gets interesting.

Result: Fair Value of $7.59 (UNDERVALUED)

However, MannKind still faces real tests, including Afrezza’s niche positioning and heavy reliance on a small product set. This could magnify any competitive or regulatory setbacks.

Next Steps

Given the mix of optimism and caution around MannKind, it makes sense to act quickly and weigh the evidence yourself before sentiment shifts again. Start with a clear view of both the upside and the risks through 3 key rewards and 1 important warning sign

Ready for more investment ideas beyond MannKind?

If MannKind has sharpened your focus, do not stop here, use the Simply Wall Street Screener to spot other stocks that could suit your portfolio goals.

• Target strong payouts and potential income resilience by reviewing companies featured in the 7 dividend fortresses.
• Hunt for potential opportunities that trade below their estimated worth by scanning the 43 high quality undervalued stocks.
• Prioritise capital protection and steadier return profiles by checking companies in the 75 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.